The GAVI alliance (former Global Alliance for Vaccines and Immunization) has recently agreed to fund the joint introductions of the HPV and rubella vaccine to nine of the 57 developing countries it serves. A total of two million women and girls will be protected from cervical cancer and a total of 588 million children will have received the rubella vaccination by 2015 if the organization’s goals are met.
Approximately 275,000 women die each year from cervical cancer- 90 percent of these women are in developing countries. If no program or change is implemented, statistics show that this number can rise to 430,000 by the year 2030. Change, however, is a viable option- the HPV vaccine has been shown to prevent 70% of cervical cancer cases.
The board’s decision will rely heavily on pharmaceutical company’s compliance and negotiations to try and secure a sustainable price for the vaccines. Earlier this year, in June, Merck announced a 67% reduction in HPV vaccine prices for the Gavi alliance, resulting in a tentative price of $5 per dose.
The Gavi board also mentioned a potential fund for distributions of a Japanese encephalitis vaccine once the World Health Organization prequalifies an effective vaccine and discussed the rollouts of pneumococcal and rotavirus vaccines to countries with high levels of unvaccinated children.